Q-omics provides the consensus-scored GSX2 profile across patient tissues and cancer cell-line models. GSX2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, GSX2 is differentially expressed in 5, with the highest sampling consensus in KICH. Additionally, GSX2 RNA expression shows 8,681 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight CESC, KICH, and TGCT as cancer lineages where GSX2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GSX2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GSX2 survival associations across molecular data types. GSX2 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GSX2 RNA expression–survival associations across cancer types. High GSX2 expression shows unfavorable associations in LGG, KICH, ACC, MESO and LUAD, but favorable associations in CESC. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .020). Together, the overview and detailed table identify CESC as the clearest survival context for GSX2 RNA expression.
This table summarizes GSX2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for GSX2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GSX2 shows lower tumor expression in KICH and BRCA and higher tumor expression in LUAD, ESCA and KIRC. The KICH box plot shows higher GSX2 RNA expression in normal versus tumor tissue (log2 FC = −0.061, t-test p < 0.001).
This table shows molecular features associated with GSX2 in patient tissues and cancer cell lines. In patient samples, GSX2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GSX2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LUNG_SCLC.
